Literature DB >> 8102926

Characterization of propranolol-resistant (-)-[125I]-cyanopindolol binding sites in rat soleus muscle.

S J Roberts1, P Molenaar, R J Summers.   

Abstract

1. The characteristics of a propranolol-resistant (-)-[125I]-cyanopindolol (CYP) binding site in rat soleus muscle were determined. 2. Saturation studies performed on homogenates of rat soleus muscle showed two phases of (-)-[125I]-CYP binding, a high affinity site (KD1 30.5 +/- 16.3 pM, Bmax 9.4 +/- 1.38 fmol mg-1 protein) and a lower affinity site (KD2 522.5 +/- 29.1 pM, Bmax 62.19 +/- 11.76 fmol mg-1 protein, n = 4). 3. In rat soleus muscle homogenates labelled with (-)-[125I]-CYP (500 pM), (-)-propranolol competition curves were biphasic with pKD values of 8.30 +/- 0.19, and 5.33 +/- 0.08, n = 7. 4. Competition between (-)-[125I]-CYP (500 pM) and (+/-)-tertatolol, (+/-)-nadolol, (+/-)-alprenolol, (+/-)-CYP, and (-) and (+)-pindolol showed that these compounds competed for binding at the propranolol-resistant site with affinities lower than those displayed at typical beta-adrenoceptors. The atypical beta-adrenoceptor agonists BRL 37344, SR58611A and ICI D7114 and the partial agonist (+/-)-CGP 12177 also competed for (-)-[125I]-CYP binding. 5. Stereoselectivity was demonstrated for the stereoisomers of alprenolol and tertalolol. The (-)-isomers of alprenolol and tertalolol had higher affinity than their corresponding (+)-isomers (3.1 and 2.6 fold respectively). These low stereoselectivity values are a characteristic of atypical beta-adrenoceptors. 6. The beta-adrenoceptor agonists, (-)-adrenaline, (-)-isoprenaline and (-)-noradrenaline, all showed lower affinity than the atypical beta-adrenoceptor agonists and competition curves appeared biphasic in nature. 7. These results confirm the presence of a propranolol-resistant (- )-[125I]-CYP binding site in rat soleus muscle. The affinities of the tested compounds at the propranolol-resistant (- )-[125I]-CYP binding site show similarities to their affinities at 'atypical' beta-adrenoceptors in adipocytes and gastrointestinal tissues and at the cloned beta 3-adrenoceptor.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8102926      PMCID: PMC2175712          DOI: 10.1111/j.1476-5381.1993.tb13576.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  53 in total

1.  Identification and characterisation of beta-adrenoceptors in guinea-pig skeletal muscle.

Authors:  M S Elfellah; J L Reid
Journal:  Eur J Pharmacol       Date:  1987-07-02       Impact factor: 4.432

Review 2.  Structural basis for functional diversity of beta 1-, beta 2- and beta 3-adrenergic receptors.

Authors:  L J Emorine; B Feve; J Pairault; M M Briend-Sutren; S Marullo; C Delavier-Klutchko; D A Strosberg
Journal:  Biochem Pharmacol       Date:  1991 Mar 15-Apr 1       Impact factor: 5.858

3.  In vitro inhibition of intestinal motility by phenylethanolaminotetralines: evidence of atypical beta-adrenoceptors in rat colon.

Authors:  A Bianchetti; L Manara
Journal:  Br J Pharmacol       Date:  1990-08       Impact factor: 8.739

4.  Characterization of beta 1- and beta 2-adrenoceptors in rat skeletal muscles.

Authors:  Y S Kim; R D Sainz; P Molenaar; R J Summers
Journal:  Biochem Pharmacol       Date:  1991-10-09       Impact factor: 5.858

5.  CGP 12177A modulates brown fat adenylate cyclase activity by interacting with two distinct receptor sites.

Authors:  J G Granneman; C J Whitty
Journal:  J Pharmacol Exp Ther       Date:  1991-02       Impact factor: 4.030

6.  Characterization of catecholamine-mediated relaxations in rat isolated gastric fundus: evidence for an atypical beta-adrenoceptor.

Authors:  D P McLaughlin; A MacDonald
Journal:  Br J Pharmacol       Date:  1991-06       Impact factor: 8.739

7.  Evidence that an atypical beta-adrenoceptor mediates the inhibition of spontaneous rhythmical contractions of rabbit isolated jejunum induced by ritodrine and salbutamol.

Authors:  B J Norman; H L Leathard
Journal:  Br J Pharmacol       Date:  1990-09       Impact factor: 8.739

8.  Expression of three human beta-adrenergic-receptor subtypes in transfected Chinese hamster ovary cells.

Authors:  K M Tate; M M Briend-Sutren; L J Emorine; C Delavier-Klutchko; S Marullo; A D Strosberg
Journal:  Eur J Biochem       Date:  1991-03-14

9.  Evidence for the existence of 'atypical' beta-adrenoceptors (beta 3-adrenoceptors) mediating relaxation in the rat distal colon in vitro.

Authors:  D P McLaughlin; A MacDonald
Journal:  Br J Pharmacol       Date:  1990-11       Impact factor: 8.739

10.  Molecular characterization of the mouse beta 3-adrenergic receptor: relationship with the atypical receptor of adipocytes.

Authors:  C Nahmias; N Blin; J M Elalouf; M G Mattei; A D Strosberg; L J Emorine
Journal:  EMBO J       Date:  1991-12       Impact factor: 11.598

View more
  13 in total

Review 1.  Agonist-induced desensitisation of β3 -adrenoceptors: Where, when, and how?

Authors:  Katerina Okeke; Stephane Angers; Michel Bouvier; Martin C Michel
Journal:  Br J Pharmacol       Date:  2019-04-07       Impact factor: 8.739

Review 2.  Tools to study beta3-adrenoceptors.

Authors:  Wim Vrydag; Martin C Michel
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-01-09       Impact factor: 3.000

3.  Comparison of three radioligands for the labelling of human beta-adrenoceptor subtypes.

Authors:  Nadja Niclauss; Martina B Michel-Reher; Astrid E Alewijnse; Martin C Michel
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2006-10-07       Impact factor: 3.000

4.  Characteristics of cyanopindolol analogues active at the beta 3-adrenoceptor in rat ileum.

Authors:  A J Hoey; C M Jackson; G G Pegg; M N Sillence
Journal:  Br J Pharmacol       Date:  1996-10       Impact factor: 8.739

5.  Biphasic effects of the beta-adrenoceptor agonist, BRL 37344, on glucose utilization in rat isolated skeletal muscle.

Authors:  Y L Liu; M A Cawthorne; M J Stock
Journal:  Br J Pharmacol       Date:  1996-03       Impact factor: 8.739

6.  Acute effects of the beta 3-adrenoceptor agonist, BRL 35135, on tissue glucose utilisation.

Authors:  Y L Liu; M J Stock
Journal:  Br J Pharmacol       Date:  1995-02       Impact factor: 8.739

7.  Characterization of beta-adrenoceptor mediated smooth muscle relaxation and the detection of mRNA for beta1-, beta2- and beta3-adrenoceptors in rat ileum.

Authors:  S J Roberts; M Papaioannou; B A Evans; R J Summers
Journal:  Br J Pharmacol       Date:  1999-06       Impact factor: 8.739

8.  Tissue functions mediated by beta(3)-adrenoceptors-findings and challenges.

Authors:  Martin C Michel; Peter Ochodnicky; Roger J Summers
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2010-06-03       Impact factor: 3.000

9.  Expression of beta 3-adrenoceptor mRNA in rat tissues.

Authors:  B A Evans; M Papaioannou; V R Bonazzi; R J Summers
Journal:  Br J Pharmacol       Date:  1996-01       Impact factor: 8.739

10.  The human near-term myometrial beta 3-adrenoceptor but not the beta 2-adrenoceptor is resistant to desensitisation after sustained agonist stimulation.

Authors:  C Rouget; M Breuiller-Fouché; F J Mercier; M J Leroy; C Loustalot; E Naline; R Frydman; T Croci; E J Morcillo; C Advenier; M Bardou
Journal:  Br J Pharmacol       Date:  2004-02-09       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.